Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bams Abila

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancers|February 11, 2023
CAR-T: What Is Next?Yi-Ju Chen, Bams Abila, Yasser Mostafa Kamel
Stroke|March 9, 2013
Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of GSK249320 in patients with strokeSteven C Cramer, Bams Abila, Nicola E Scott, et al.
Acta Neuropathologica Communications|December 17, 2014
Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology studySafa Al-Sarraj, Andrew King, Matt Cleveland, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancers|February 11, 2023
CAR-T: What Is Next?Yi-Ju Chen, Bams Abila, Yasser Mostafa Kamel
Stroke|March 9, 2013
Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of GSK249320 in patients with strokeSteven C Cramer, Bams Abila, Nicola E Scott, et al.
Acta Neuropathologica Communications|December 17, 2014
Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology studySafa Al-Sarraj, Andrew King, Matt Cleveland, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
Pageof 1